BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Negro F. Natural history of NASH and HCC. Liver Int 2020;40:72-6. [DOI: 10.1111/liv.14362] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Majeed CN, Ahmad MI, Ahsan I, Anees MA, Maheshwari SK, Soliman EZ. Response to the Letter to the Editor. Ann Noninvasive Electrocardiol 2020;25:e12756. [PMID: 32154617 DOI: 10.1111/anec.12756] [Reference Citation Analysis]
2 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Oyama A, Nouso K, Yoshimura K, Morimoto Y, Nakamura S, Onishi H, Takaki A, Iwadou S, Kariyama K, Kuwaki K, Yabushita K, Sakaguchi K, Toshimori J, Kobashi H, Moriya A, Ando M, Okada H; Okayama Hepatocellular Carcinoma Study Group. Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2021;51:694-701. [PMID: 33687130 DOI: 10.1111/hepr.13633] [Reference Citation Analysis]
4 Jarvis H, O'Keefe H, Craig D, Stow D, Hanratty B, Anstee QM. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open 2022;12:e049767. [PMID: 34983755 DOI: 10.1136/bmjopen-2021-049767] [Reference Citation Analysis]
5 Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers (Basel) 2020;12:E2729. [PMID: 32977536 DOI: 10.3390/cancers12102729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cremonese C, Schierwagen R, Uschner FE, Torres S, Tyc O, Ortiz C, Schulz M, Queck A, Kristiansen G, Bader M, Sauerbruch T, Weiskirchen R, Walther T, Trebicka J, Klein S. Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. Int J Mol Sci 2020;21:E3308. [PMID: 32392802 DOI: 10.3390/ijms21093308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sharma N, Biswas S, Al-Dayan N, Alhegaili AS, Sarwat M. Antioxidant Role of Kaempferol in Prevention of Hepatocellular Carcinoma. Antioxidants (Basel) 2021;10:1419. [PMID: 34573051 DOI: 10.3390/antiox10091419] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Reference Citation Analysis]
9 Tan Y, Lin XT, Luo YD, Zhang J, Fang L, Zhu YY, Yu HQ, Shuai L, Jiang Y, Zhang LD, Bie P, Xie CM. Reduced IκBα promotes hepatocellular carcinoma cell proliferation and migration via regulation of NF-κB/Erbin axis. Oncol Lett 2020;20:216. [PMID: 32963622 DOI: 10.3892/ol.2020.12079] [Reference Citation Analysis]
10 Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'Alteroche L, Portal I, Lapidus N, Pol S, Carrat F; ANRS/AFEF Hepather study group. Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clin Res Hepatol Gastroenterol 2021;45:101713. [PMID: 33930591 DOI: 10.1016/j.clinre.2021.101713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, Mobasseri M, Ostadrahimi A. Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study. Clin Res Hepatol Gastroenterol 2021;45:101754. [PMID: 34303827 DOI: 10.1016/j.clinre.2021.101754] [Reference Citation Analysis]
12 Yamamoto K, Honda T, Yokoyama S, Ma L, Kato A, Ito T, Ishizu Y, Kuzuya T, Nakamura M, Kawashima H, Ishigami M, Tsuji NM, Fujishiro M. Microbiome, fibrosis and tumor networks in a non-alcoholic steatohepatitis model of a choline-deficient high-fat diet using diethylnitrosamine. Dig Liver Dis 2021;53:1443-50. [PMID: 33726979 DOI: 10.1016/j.dld.2021.02.013] [Reference Citation Analysis]
13 Uchida D, Takaki A, Oyama A, Adachi T, Wada N, Onishi H, Okada H. Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. Nutrients 2020;12:E1576. [PMID: 32481552 DOI: 10.3390/nu12061576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
14 Matboli M, Gadallah SH, Rashed WM, Hasanin AH, Essawy N, Ghanem HM, Eissa S. mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:6770. [PMID: 34202571 DOI: 10.3390/ijms22136770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
16 Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol 2021; 27(13): 1267-1282 [PMID: 33833481 DOI: 10.3748/wjg.v27.i13.1267] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Reference Citation Analysis]
18 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Meng L, Goto M, Tanaka H, Kamikokura Y, Fujii Y, Okada Y, Furukawa H, Nishikawa Y. Decreased Portal Circulation Augments Fibrosis and Ductular Reaction in Nonalcoholic Fatty Liver Disease in Mice. Am J Pathol 2021;191:1580-91. [PMID: 34119474 DOI: 10.1016/j.ajpath.2021.06.001] [Reference Citation Analysis]
20 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
21 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
23 Tutunchi H, Naeini F, Mobasseri M, Ostadrahimi A. Triglyceride glucose (TyG) index and the progression of liver fibrosis: A cross-sectional study. Clin Nutr ESPEN 2021;44:483-7. [PMID: 34330512 DOI: 10.1016/j.clnesp.2021.04.025] [Reference Citation Analysis]
24 Márquez-Quiroga LV, Arellanes-Robledo J, Vásquez-Garzón VR, Villa-Treviño S, Muriel P. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma. Biochem Pharmacol 2022;195:114845. [PMID: 34801522 DOI: 10.1016/j.bcp.2021.114845] [Reference Citation Analysis]
25 Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ. Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. Biochem Biophys Res Commun 2021;588:154-60. [PMID: 34971904 DOI: 10.1016/j.bbrc.2021.12.065] [Reference Citation Analysis]
26 Gadallah SH, Eissa S, Ghanem HM, Ahmed EK, Hasanin AH, El Mahdy MM, Matboli M. Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. Biomed Pharmacother 2021;140:111781. [PMID: 34090052 DOI: 10.1016/j.biopha.2021.111781] [Reference Citation Analysis]
27 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Reference Citation Analysis]
28 Nakanishi N, Hashimoto Y, Okamura T, Ohbora A, Kojima T, Hamaguchi M, Fukui M. A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. Sci Rep 2021;11:19992. [PMID: 34620897 DOI: 10.1038/s41598-021-99036-y] [Reference Citation Analysis]
29 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]